Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
AuthorsRadford, John A
AffiliationThe University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom;
MetadataShow full item record
AbstractThe safety and activity of obinutuzumab (GA101) plus chemotherapy in relapsed/refractory follicular lymphoma was explored in 56 patients. Participants received GA101 plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP; every 3 weeks, 6-8 cycles) or GA101 plus fludarabine and cyclophosphamide (G-FC; every 4 weeks, 4-6 cycles). Patients were randomized to either GA101 1,600 mg on days 1 and 8 of cycle 1 followed by 800 mg on day 1 of subsequent cycles or 400 mg for all doses. Treatment responders were eligible for GA101 maintenance (3-monthly). Grade 1/2 infusion-related reactions (IRRs) were the most common treatment-related adverse event (AE) (all grades: G-CHOP, 68%; G-FC, 82%). Grade 3/4 IRRs were rare (7%) and restricted to first infusion. All patients received the planned GA101 dose. Neutropenia was the most common treatment-related hematologic AE for G-CHOP (43%) and G-FC (50%). At induction end, 96% (27/28; CR, 39% [11/28]) of patients receiving G-CHOP and 93% (26/28; CR, 50% [14/28]) receiving G-FC achieved responses. GA101 plus CHOP or FC had an acceptable safety profile, with no new or unexpected AEs, but G-FC was associated with more AEs than G-CHOP. GA101 plus chemotherapy resulted in 93% to 96% response rates, supporting phase 3 investigation. (Registered at www.clinicaltrials.gov: NCT00825149).
CitationObinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). 2013: Blood
- Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.
- Authors: Grigg A, Dyer MJ, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E, Marlton P
- Issue date: 2017 Apr
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
- Authors: Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD
- Issue date: 2016 Aug
- Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
- Authors: Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang Y, Paulson JN, Chang YM, Musick L, Abrisqueta P
- Issue date: 2021 Dec
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
- Authors: Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE
- Issue date: 2018 Aug 10
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
- Authors: Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH
- Issue date: 2017 Nov 1